Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
VERV Verve Therapeutics
23.290-0.720-3.00%
Close
02/03 16:00 ET
23.2900.0000.00%
Post Mkt Price 02/03 16:01 ET
High
24.290
Open
23.230
Turnover
13.22M
Low
22.920
Pre Close
24.010
Volume
561.35K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $40.00 Average Target Price From Analysts
Shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) have been assigned an average recommendation of "Hold" from the seven brokerages that are currently covering the stock, Marketbeat repor
Verve Therapeutics (NASDAQ:VERV) Shares Down 4.7%
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) fell 4.7% during trading on Wednesday . The stock traded as low as $21.51 and last traded at $21.67. 178,318 shares traded hands during mid-day tra
Insiders Who Bought Into Verve Therapeutics, Inc. (NASDAQ:VERV) Earlier This Year Might Wish They'd Invested More as Stock Gained 7.1%
Verve Therapeutics, Inc. (NASDAQ:VERV) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 7.1% resulting in a US$98m addition to the company's mar
Editas, Beam Win Bullish Views as Cantor Launches Gene Editing Coverage
Verve Therapeutics Price Target Announced at $21.00/Share by Cantor Fitzgerald
Verve Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/01/2023 -7.69% Cantor Fitzgerald → $21 Initiates Coverage On → Neutral 12/15/2022 -42.86% Goldman Sachs
Cantor Fitzgerald Initiates Coverage On Verve Therapeutics With Neutral Rating, Announces Price Target of $21
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Neutral rating and announces Price Target of $21.
Verve Therapeutics Initiated With a Neutral at Cantor Fitzgerald
MGNI, BIOR and VERV Are Among After Hour Movers
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down to $22.13
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) shares gapped down prior to trading on Friday . The stock had previously closed at $22.13, but opened at $21.10. Verve Therapeutics shares last tra
Company Overview
More
Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Boston, MA.
CEO： Dr. Sekar Kathiresan, M.D.
Market： NASDAQ
Listing Date： 06/17/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet